The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

verseon.com

Founded Year

2002

Stage

Loan | Alive

Total Raised

$32.88M

Last Raised

$1.5M | 2 yrs ago

About Verseon Corp

Verseon develops a systematic, computationally-driven solution to achieve the molecular modeling accuracy necessary for rapid and cost-effective drug discovery. Verseon plans to use its platform to establish a diversified discovery pipeline across multiple disease areas. Current drug programs include anticoagulation, diabetic macular edema, and oncology (solid tumors).

Verseon Corp Headquarter Location

47071 Bayside Parkway

Fremont, California, 94538,

United States

510-225-9000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Verseon Corp

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Verseon Corp is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

D

Diabetes

1,750 items

B

Biopharma Tech

838 items

Verseon Corp Patents

Verseon Corp has filed 24 patents.

The 3 most popular patent topics include:

  • Coagulation system
  • G protein coupled receptors
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/27/2018

5/19/2020

Coagulation system, Coagulopathies, EC 3.4.21, Anticoagulants, Clusters of differentiation

Grant

Application Date

3/27/2018

Grant Date

5/19/2020

Title

Related Topics

Coagulation system, Coagulopathies, EC 3.4.21, Anticoagulants, Clusters of differentiation

Status

Grant

Latest Verseon Corp News

10:46 EDT Drug-discovery pioneer Verseon delivers breakthrough once predicted by Steve Jobs

May 16, 2022

News provided by Share this article Share this article LONDON, May 16, 2022 /PRNewswire/ -- Apple's visionary founder Steve Jobs once said, "The biggest innovations of the 21st century will be at the intersection of biology and technology." Silicon Valley-based Verseon now sees itself at this juncture after building a proprietary physics-and AI-driven technology platform to create new drugs atom by atom. Drug-discovery pioneer Verseon delivers breakthrough once predicted by Steve Jobs (PRNewsfoto/Verseon) Verseon's Chief Technology Officer Sangtae Kim, a member of the US National Academy of Engineering, says the platform is far more sophisticated than the "AI systems" of other drug developers, as it enables Verseon to design the entirely new chemical structures needed to fight currently untreatable diseases. He points out that the effectiveness of AI critically depends on the amount and quality of data available for its training. But other current AI drug-discovery companies only have data from the small pool of existing drugs and past trial-and-error experiments, severely limiting their ability to find completely novel drug molecules. Anirban Datta, Verseon's Head of Biology, wrote in Drug Discovery Online  that "there are many orders of magnitude more potential small molecule drugs … than are represented in available data." As recently highlighted in Impact Wealth Magazine , Verseon's founders realized that systematic design of completely new drugs requires breakthroughs in molecular-physics modeling to determine how new chemical structures will bind to a disease-causing protein. Using its platform, Verseon has identified multiple clinical candidates for every one of its programs – a feat unheard of in the pharmaceutical industry. The company is not only bringing much-needed new treatments to market for killers like cancers and heart disease, but also developing products that slow human aging and boost longevity. BioSpace 's Gail Dutton recently observed that Verseon "is beginning to fill in the map of uncharted drug discovery space. In effect, it is replacing the void of 'here be dragons' (as one 16th-century mapmaker warned ) with islands of known entities." She therefore concluded that Verseon is "changing the paradigm of drug discovery." Verseon's management team members have previously made transformational breakthroughs in various fields. Co-founders Adityo Prakash and Eniko Fodor developed technologies now owned by Intel that power all video streaming today, from Amazon Prime to Zoom. The third Verseon founder, David Kita, developed one of the first bioinformatics platforms that catalyzed novel gene detection during the genomics revolution. And Sangtae Kim – a former VP at major pharma company Eli Lilly and Chair of Purdue's Chemical Engineering Division – now drives further enhancement of Verseon's powerful AI and proprietary data sets. "Verseon's platform comprises significant new advances within multiple distinct branches of science," says Kim. "It is by far the most advanced ab initio drug design methodology currently in existence." Verseon is currently trialling drugs with remarkably low bleeding risk to treat and prevent heart attacks and strokes in over 400 million patients worldwide. Uncontrolled bleeding is the biggest risk factor associated with current alternatives. One of the world's leading cardiologists, Professor John Deanfield of University College London, commented: "Verseon's platelet-sparing anticoagulants…represent an exciting 'precision medicine' opportunity for the treatment of a large population of cardiovascular disease patients." The company is also developing oral drugs to treat diabetic vision loss in over 154 million patients and three different programs to fight cancer – one of the world's biggest killers. All of these are part of a fast-growing drug pipeline of 16 candidate drugs across eight programs. Pfizer's former SVP of R&D Strategy Robert Karr commented: "Verseon's platform is finally ushering in the age of systematic discovery and development of novel drugs."

Verseon Corp Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Verseon Corp Rank

  • When was Verseon Corp founded?

    Verseon Corp was founded in 2002.

  • Where is Verseon Corp's headquarters?

    Verseon Corp's headquarters is located at 47071 Bayside Parkway, Fremont.

  • What is Verseon Corp's latest funding round?

    Verseon Corp's latest funding round is Loan.

  • How much did Verseon Corp raise?

    Verseon Corp raised a total of $32.88M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.